Skip to main content
Aprogen, Inc logo

Aprogen, Inc — Investor Relations & Filings

Ticker · 007460 ISIN · KR7007460009 KO Manufacturing
Open in API
Filings indexed 718 across all filing types
Latest filing 2026-04-15 Regulatory Filings
Country KR South Korea
Listing KO 007460

About Aprogen, Inc

https://www.aprogen.com/en/v.do?a=Main

Aprogen, Inc. is a biopharmaceutical company focused on the research, development, and manufacturing of biologic medicines. The company's core activities are centered on developing both biosimilars and novel drugs, including new protein therapeutics and bispecific antibodies. Its product development is based on proprietary technologies in antibody engineering and recombinant protein engineering.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항
Regulatory Filings Classification · 1% confidence The document is a short regulatory disclosure under KRX headings (“투자판단 관련 주요경영사항”), announcing a board decision to terminate an exclusive license agreement. It is not a full annual or interim report, earnings release, investor presentation, or any specialized category. This fits the miscellaneous regulatory announcement category (RNS).
2026-04-15 Korean
타인에대한담보제공결정(자회사의 주요경영사항)
Capital/Financing Update Classification · 1% confidence The document is a Korean regulatory announcement titled “타인에 대한 담보제공 결정” (Decision to Provide Collateral to a Third Party). It details a board resolution to secure financing by pledging company assets as collateral, including amounts, counterparties, periods, and links to prior related disclosures. This is not an earnings release, call transcript, AGM material, or an annual/interim report, nor is it about board member changes or dividends. It directly concerns a financing activity (providing guarantees/collateral), fitting the “Capital/Financing Update” category (CAP).
2026-04-13 Korean
주요사항보고서(유상증자결정)(자회사의 주요경영사항)
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory disclosure (“주요사항보고서”) filed with the Financial Services Commission and Korea Exchange, detailing the terms of a paid-in capital increase (유상증자 결정) including number of new shares, issue price, allotment method (제3자배정), schedule, and related financial information. This is a direct announcement of a share issuance/capital change, matching the definition of “Share Issue/Capital Change” (Code: SHA).
2026-04-13 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a Korean major items report (“주요사항보고서”) notifying investors and regulators of the issuance (and amendment) of convertible bonds, detailing purposes of fund raising, bond terms, conversion terms and adjustment mechanisms. This is a financing/capital structure update rather than an earnings release, management commentary, or AGM material. It falls squarely under Capital/Financing Update (CAP).
2026-04-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a ‘주식등의 대량보유상황보고서(일반)’ – a statutory disclosure of large shareholdings and changes in major share ownership under Korean capital markets law. It details share amounts, percentages, changes, special relationships, and contractual arrangements for significant shareholders. This aligns with the “Major Shareholding Notification” category (Code: MRQ).
2026-04-03 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a ‘주요사항보고서’ filed to the Korea Exchange / Financial Services Commission detailing a paid‐in capital increase decision (유상증자결정) via third‐party allotment. It contains specifics on new share issuance: number of new ordinary shares, issuance price, base price calculation, allotment rationale, fund usage, and subscriber details. This is precisely an announcement regarding a new share issue (capital change). Therefore, it falls under “Share Issue/Capital Change” (Code: SHA).
2026-04-02 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.